Suggested remit - To appraise the clinical and cost-effectiveness of acalabrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia
Status In progress
Process STA 2018
ID number 1613

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 09 September 2019 - 04 October 2019

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 May 2019 In progress, Referred 05 December 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance